|
|
BY OUR PHARMA CORRESPONDENT
13 September,2005: The product, whose patent recently expired, was shipped to clients at patent expiry. The first orders were around 10 million tablets and the company estimates that Terbinafine will become the Group’s highest selling ant ifungal - medicine. The product is still not expected to reach the Group’s ten highest selling products.
Terbinafine is a well known medicine, mainly used in the treatment of fungal infection in skin and nails. Terbinafine from Actavis is distributed in tablets in two strengths, but the company is also developing a Terbinafine cream. The product was originally launched in the UK in 1990, but its patent expired recently.
The product is manufactured and packaged by Actavis in Malta, and Actavis’ subsidiary Medis will handle the sale of the product in Europe under customer label, but Actavis Nordic will distribute the product in own-label in the Nordic countries. The product has been available in Iceland for a few years.
Founded in 1956, the Actavis Group now operates across five continents and has its headquarters in Iceland. Principal markets include Turkey, Germany, Bulgaria, Serbia, Russia and recently the US with the acquisition of Amide. It has a total workforce of around 7,000.
Actavis has modern manufacturing facilities in Bulgaria, Malta, Turkey, the US and Iceland that are EU-GMP (Good Manufacturing Practice) approved. The manufacturing facility in the US is FDA approved. Additional manufacturing in Serbia currently services domestic and other markets for own-label products outside the
EU.
BY OUR PHARMA CORRESPONDENT |
